Cadrenal Therapeutics Inc
CVKD
Company Profile
Business description
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Contact
822 A1A North
Suite 306
Ponte VedraFL32082
USAT: +1 904 300-0701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 7.20 | 0.08% |
| CAC 40 | 8,089.23 | 78.50 | -0.96% |
| DAX 40 | 23,981.47 | 223.89 | -0.92% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,497.90 | 13.77 | 0.13% |
| HKSE | 25,321.34 | 446.74 | -1.73% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,278.06 | 1,000.99 | -1.78% |
| NZX 50 Index | 13,617.89 | 2.32 | -0.02% |
| S&P 500 | 6,816.63 | 52.87 | -0.77% |
| S&P/ASX 200 | 8,940.30 | 3.30 | 0.04% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |